Fli1 Is a Negative Regulator of Estrogen Receptor α in Dermal Fibroblasts  by Hattori, Tomoyasu et al.
Fli1 Is a Negative Regulator of Estrogen Receptor a in
Dermal Fibroblasts
Tomoyasu Hattori1, Lukasz Stawski1, Sashidhar S. Nakerakanti1 and Maria Trojanowska1
Estrogen is an important regulator of dermal fibroblast functions, including extracellular matrix (ECM) synthesis.
Estrogen mediates its effects through estrogen receptors (ERs), ERa and ERb; however, regulation of ERs in
dermal fibroblasts remains poorly understood. Friend leukemia integration factor 1 (Fli1), a member of the Ets
transcription factor family, has been shown to play a pivotal role in regulation of the ECM genes in dermal
fibroblasts. The aim of this study was to examine a possible interaction between Fli1 and estrogen pathways,
focusing on ERa. We show that treatment of human dermal fibroblasts with transforming growth factor-b
(TGF-b) increases ERa protein and mRNA levels. Similarly, ERa expression was increased in response to small
interfering RNA (siRNA)-mediated depletion of Fli1, suggesting that Fli1 is a mediator of the TGF-b effects on ERa
expression. Accordingly, we showed that Fli1 binds to the most proximal region of the ERa promoter, and
dissociates from the promoter upon TGF-b treatment. An inverse correlation between Fli1 and ERa expression
levels was confirmed in cultured skin fibroblasts obtained from Fli1þ /– mice and in the skin of Fli1þ /– mice
in vivo. This study supports a role of Fli1 as a negative regulator of the ERa gene in dermal fibroblasts.
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INTRODUCTION
Friend leukemia integration factor 1 (Fli1) is a member of the
Ets transcription factor family characterized by the presence
of the evolutionarily conserved DNA-binding domain (ETS
domain) that recognizes the purine-rich GGA(A/T) core
sequence (Ets-binding site (EBS)). Fli1 is highly expressed in
hematopoietic cell lineages and in vascular endothelial cells
(Hollenhorst et al., 2004). It plays an important role in
megakaryocytic differentiation (Spyropoulos et al., 2000) and
in vascular homeostasis (Asano et al., 2010). Specifically, in
endothelial cells Fli1 regulates genes involved in vessel
maturation and stabilization (Asano et al., 2010). Although
Fli1 expression in dermal fibroblasts is relatively low, recent
studies have shown that Fli1 plays a pivotal role in the
regulation of the extracellular matrix (ECM) genes, including
type I collagen (Czuwara-Ladykowska et al., 2001; Kubo
et al., 2003; Asano et al., 2009), tenascin-C (Shirasaki et al.,
1999), matrix metalloproteinase 1 (MMP-1) (Jinnin et al.,
2005), and the multifunctional matricellular factor CTGF/
CCN2 (Nakerakanti et al., 2006). Transforming growth
factor-b (TGF-b) regulates transcriptional activity of Fli1
through post-translational modifications, including protein
kinase C-d (PKC-d)-dependent phosphorylation and subse-
quent p300-CBP associated factor–dependent acetylation
(Asano et al., 2007; Asano and Trojanowska, 2009).
Estrogen affects many aspects of skin physiology. It
increases skin thickness and collagen content (Varila et al.,
1995; Rittie et al., 2008), decreases fine wrinkles (Creidi et al.,
1994), accelerates wound healing (Ashcroft et al., 1999), and
changes the quality of scarring (Ashcroft et al., 1997). Estrogen
exerts its actions through the well-characterized estrogen
receptors (ERs), ERa and ERb; however, their specific roles in
the skin have not been fully defined. Furthermore, the
expression profile of the two ERs varies according to location
and tissue type, suggesting that each has different, cell-specific
roles (Hall and Phillips, 2005). ERs function as ligand-inducible
transcription factors, and ligand-bound ERs can bind directly to
estrogen response elements in the promoters of target genes, or
they can interact with other transcription factor complexes like
Jun/Fos (Kushner et al., 2000) or specificity protein 1 (Saville
et al., 2000) and influence transcription of genes whose
promoters do not harbor estrogen response elements.
Previous studies using various experimental models have
shown the inhibitory effects of estrogen on TGF-b signaling
through direct interaction between Smad2/3 and ERa
(Matsuda et al., 2001; Ito et al. 2010). Because our recent
studies have demonstrated the importance of Fli1 in the
TGF-b signaling in dermal fibroblasts, in this study we wished
to examine the potential relationship between the TGF-b/Fli1
and the estrogen pathways focusing on ERa. We found that
Fli1 functions as a negative transcriptional regulator of the
ERa gene in dermal fibroblasts both in vivo and in vitro,
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suggesting that some of the pathogenic effects of Fli1
downregulation in cutaneous fibrosis and chronic wound
healing (Kubo et al., 2003; Sakthianandeswaren et al., 2010)
could be mediated by the upregulation of estrogen/ERa
signaling.
RESULTS
TGF-b upregulates ERa expression in human dermal fibroblasts
via Fli1-mediated pathway
The presence of both ER isoforms has previously been
documented in dermal fibroblasts in vitro and in the skin
in vivo (Thornton et al., 2003; Haczynski et al., 2004;
Pelletier and Ren, 2004; Yoo et al., 2007). As according to a
recent study ERa represents a predominant isoform expressed
in human dermal fibroblasts (Rittie et al., 2008), we focused
on this isoform and first confirmed its expression by reverse
transcription-PCR (RT-PCR) (Figure 1a) and western blot
(Figure 1b). MCF-7 breast cancer cells, which express full-
length ERa, as well as 46 and 36 kDa splice variants (Flouriot
et al., 2000; Wang et al., 2005), were used as a positive
control. As shown in Figure 1b, dermal fibroblasts express
full-length and a 46 kDa isoform of ERa, although at much
lower level than MCF-7.
We next examined the effect of TGF-b1 on expression of
ERa in human dermal fibroblasts by western blot and
quantitative real-time RT-PCR. TGF-b1 consistently increased
the levels of ERa protein and mRNA 24hours after stimula-
tion (Figure 1c), which correlated with an increase in
COL1A1 (collagen, type I, a1) mRNA expression (data not
shown).
As Fli1 mediates some of the TGF-b effects in dermal
fibroblasts, we examined whether Fli1 also contributes to the
ERa expression by depleting Fli1 using small interfering RNA
(siRNA). Treatment of fibroblasts with 10 nM of Fli1 siRNA for
72 hours resulted in a reduction of Fli1 mRNA and protein
levels byB90% (Figure 2a). As shown in Figure 2b, depletion
of Fli1 resulted in upregulation of both ERa protein (1.82-fold)
and mRNA (1.44-fold). The increase was comparable with
the TGF-b1-induced ERa levels. These observations suggest
that Fli1 might be a primary regulator of ERa expression
downstream of TGF-b signaling in human dermal fibroblasts.
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Figure 1. Estrogen receptor a (ERa) mRNA and protein expression is
upregulated by transforming growth factor-b (TGF-b) in human dermal
fibroblasts. (a) Reverse transcription-PCR (RT-PCR) analysis of ERa in
fibroblasts. (b) Western blot analysis of ERa protein in fibroblasts (50 mg) and
MCF-7 cells (30 mg). The blots were reprobed with anti-b-actin antibody.
(c) Western blot of ERa protein determined in serum-starved dermal
fibroblasts treated with transforming growth factor-b1 (TGF-b1; 2 ngml–1) for
24 hours. Representative data of three independent experiments are shown
with quantitative representation obtained by densitometric analysis (lower left
panel). ERa mRNA levels were determined by quantitative RT-PCR (lower
right panel). Values are normalized relative to control (arbitrarily set as 1).
Means±SD of three independent experiments is shown. *Po0.05 (Student’s
t-test) versus control.
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Figure 2. Friend leukemia integration factor 1 (Fli1) downregulation induces
estrogen receptor a (ERa) expression. (a) Fli1 protein and mRNA levels and
(b) ERa protein and mRNA levels after small interfering RNA (siRNA)-
mediated Fli1 depletion in dermal fibroblasts. Cells were transfected with
either 10 nM of Fli1 siRNA or corresponding concentration of control siRNA.
After 48 hours, cells were serum-starved to remove the effect of serum. Cells
were harvested 72 hours after transfection. Protein levels of Fli1 and ERa were
determined by western blot. The blots were reprobed with anti-b-actin
antibody, and representative data of three independent experiments are
shown. mRNA levels of Fli1 and ERa were determined by quantitative
RT-PCR. Means±SD of three independent experiments is shown, with values
normalized to control (arbitrarily set at 1). *Po0.01 (Student’s t-test)
versus control.
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Fli1 interacts with the ERa promoter in vivo
Transcription of ERa is directed by at least seven different
promoters, resulting in mRNAs that differ in 50 untranslated
regions (Figure 3a) (Kos et al., 2001). As promoter usage
varies among tissues and cell types (Reid et al., 2002), we
examined the promoter usage in dermal fibroblasts. For this
experiment, forward primers specific for the 50 untranslated
region of the ERa mRNA produced from each promoter were
coupled with a common reverse primer directed toward exon
1 for RT-PCR analyses. As shown in Figure 3b, dermal
fibroblasts primarily utilized promoter A; however, all of the
promoters were employed to different extents, consistent with
previous report in MCF-7 cells (Murphy et al., 2009).
Promoter A is the most proximal promoter of the human
ERa gene (Murphy et al., 2009). Analysis of the 1,300 bp
sequence, which includes both promoters A and B, by
Tfsitescan (www.ifti.org) program revealed four potential
EBSs (Figure 3c). To determine if Fli1 interacts with the ERa
promoter region, we used the chromatin immunoprecipita-
tion (ChIP) assay and the DNA affinity precipitation assay.
Crosslinked chromatin was immunoprecipitated with an
antibody to Fli1, and the purified genomic DNA was
amplified with three sets of primers specific for each putative
binding site within promoter A (Figure 3c). As shown in
Figure 3d, Fli1 occupies the 681 to 523 and the 458 to
298 regions, but not the 1,300 to 1,090 region of
promoter A in the absence of TGF-b1 stimulation. Upon TGF-
b1 stimulation, Fli1 binding to these regions remained
unchanged at 3 hours, but was no longer detectable at
24 hours (Figure 3d). ChIP without antibody did not yield a
significant amount of bound DNA.
The results of the ChIP analyses were further validated by
DNA affinity precipitation assay. Biotinylated oligonucleo-
tide sequences representing putative EBSs in the proximal
ERa promoter were used in binding reactions with cell
extracts enriched with Fli1 protein, which were obtained
from cells with ectopic Fli1 expression. As presented in
Figure 3e, and consistent with ChIP analysis, we observed
strong and specific Fli1 binding to the 375 site. The 681 to
523 region, which showed a weak binding in the ChIP
assay, encompasses two potential EBSs. Fli1 showed specific
binding to the 577 site, but not the 630 site. A weak
binding was also observed to the 1,223 site. Taken together,
these data suggest that the 375 site in the proximal ERa
promoter may represent a principal response element for Fli1
in this promoter region.
To study the functional role of Fli1 in regulating ERa
promoter activity, we performed co-transfections of Fli1 and
the 3,000 bp fragment of the ERa promoter linked to the
luciferase reporter gene. As shown in Figure 3f, overexpres-
sion of Fli1 abrogated ERa promoter activity by 50%, thus
supporting the role of Fli1 as a negative regulator of the ERa
gene. Consistent with the mRNA data, TGF-b treatment
enhanced ERa promoter activity in the presence of control
vector. However, unexpectedly, overexpression of Fli1
enhanced the effects of TGF-b, suggesting that the additional
indirect effects of Fli1 overexpression may influence the
effects of TGF-b in this assay.
Expression of ERa is elevated in Fli1+/– mouse fibroblasts
To further investigate the role of Fli1 in the ERa expression,
we used mice carrying a targeted disruption of Fli1. As Fli1–/–
mouse embryos die by day 12.5 (Hart et al., 2000;
Spyropoulos et al., 2000), Fli1þ /– mice were used. First,
dermal fibroblasts were isolated from female Fli1þ /þ and
Fli1þ /– mice, and the effect of Fli1 downregulation on ERa
expression in cultured dermal fibroblasts was determined by
western blot and quantitative RT-PCR analyses. As expected,
the levels of Fli1 protein and mRNA in fibroblasts from
Fli1þ /– mice were reduced by B50% relative to fibroblasts
from Fli1þ /þ mice (Figure 4a), whereas ERa expression was
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Figure 3. Friend leukemia integration factor 1 (Fli1) occupies the estrogen
receptor a (ERa) promoter. (a) ERa promoter (Kos et al., 2001). (b) ERa
promoter utilization in dermal fibroblasts. Reverse transcription-PCR
(RT-PCR) was performed using forward primers specific for each upstream
exon and a reverse primer specific for exon 1. (c) ERa promoter A; Ets binding
sites (closed ovals). (d) Chromatin immunoprecipitation (ChIP) assay of Fli1
occupancy of the promoter A. (e) Fli1 binding to the Ets sites in the ERa
promoter using 50 end-labeled wild-type (WT) and mutated at the Ets site
(MUT) oligonucleotides. (f) Co-transfections of ERa-Luc with empty or Fli1
expression vector in fibroblasts with or without transforming growth factor-b
(TGF-b) stimulation (Tb), normalized using pSV-b-galactosidase. The values
depicted are means±SE of four experiments, *Po0.05.
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upregulated at both the protein (2.5-fold) and mRNA (1.9-
fold) levels in Fli1þ /– fibroblasts (Figure 4b). These data are
consistent with the results obtained from Fli1 siRNA-treated
human dermal fibroblasts, indicating an inverse relationship
between expression of Fli1 and ERa in dermal fibroblasts.
We next examined the expression pattern of ERa in mouse
skin by immunohistochemistry. Sections from dorsal skin of
female Fli1þ /þ and Fli1þ /–mice were immunostained with a
specific antibody against mouse ERa. As reported previously
(Thornton et al., 2003; Pelletier and Ren, 2004), high
expression of ERa protein was detected in the sebaceous
gland of skin from both Fli1þ /þ and Fli1þ /–mice (Figure 4c).
Relatively high expression of ERa was also detected in the
epidermis and hair follicles. Significant difference in ERa
expression pattern was observed in the dermis. In Fli1þ /–
mice, the majority of dermal cells with fibroblastic morphol-
ogy expressed ERa, whereas only moderate expression of ERa
was observed in the dermis of Fli1þ /þ mice (Figure 4c). To
quantify these differences, ERa-positive fibroblasts were
counted in the dermis of Fli1þ /þ and Fli1þ /– mice. The
relative proportion of positive ERa fibroblasts was 2.5-fold
higher in Fli1þ /– mice than in Fli1þ /þ mice (Figure 4d).
These results support the conclusion that Fli1 is a functional
negative regulator of ERa gene in dermal fibroblasts.
To determine whether changes in ERa expression levels
have functional consequences with respect to matrix synth-
esis, collagen mRNA and protein levels were examined in
Fli1þ /þ and Fli1þ / fibroblasts after treatment with the ERa
activator, 17b-estradiol, or the ERa inhibitor, tamoxifen. As
shown in Figure 5, treatment with tamoxifen decreased basal
COL1A1 mRNA and protein levels, suggesting that ER
signaling contributes to collagen expression and synthesis
in dermal fibroblasts. In agreement with previous reports,
Fli1þ / fibroblasts produced elevated levels of collagen
(Kubo et al., 2003). Furthermore, fibroblasts obtained
from Fli1þ / mice showed more pronounced responses to
both tamoxifen and 17b-estradiol. For example, tamoxifen
reduced basal levels of COL1A1 mRNA by B15% in wild-
type (WT) male fibroblasts versus B31% in Fli1þ / male
fibroblasts (Figure 5a). The response to tamoxifen was greater
in female fibroblasts withB39% reduction in WT fibroblasts
and B54% reduction in Fli1þ / fibroblasts (Figure 5b). On
the other hand, response to 17b-estradiol was in general
stronger in male fibroblasts with B66% increase in Col1A1
in WT fibroblasts andB112% increase in Fli1þ / fibroblasts
(Figure 5a). In WT female fibroblasts, the increase of COL1A1
mRNA was B83 versus B49% in Fli1þ / fibroblasts (Figure
5b). Similar responses were also observed at the collagen
protein level. Together, these experiments support a profi-
brotic role for ERa in dermal fibroblasts.
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Figure 4. Estrogen receptor a (ERa) levels are elevated in Fli1þ /– mouse
fibroblasts and in the skin in vivo. Protein and mRNA levels of (a) friend
leukemia integration factor 1 (Fli1) and (b) ERa in dermal fibroblasts from
female Fli1þ /þ and Fli1þ /–mice. The value was normalized relative to that of
Fli1þ /þ mouse fibroblasts (arbitrarily set as 1) and means±SD of three
experiments are shown. *Po0.05. (c) Immunodetection of ERa in skin
samples from Fli1þ /þ and Fli1þ /– mice. Original magnification is 200-fold
(upper panels) and 400-fold (lower panels). Scale bar¼ 0.02mm. (b) The
relative proportion of ERa-positive fibroblasts in dermis. At least 100
fibroblasts were counted for each specimen. The value was normalized
relative to that of Fli1þ /þ mouse skin (arbitrarily set as 1) and means±SD of
three mice are shown. *Po0.05.
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DISCUSSION
Fli1 has emerged as an important regulator of ECM synthesis
in the skin (Asano et al., 2009) and other organs (Elkareh
et al., 2009). Although it is well established that Fli1 is a
transcriptional repressor of the interstitional collagen genes,
other functions of Fli1 in dermal fibroblasts have not been
fully examined. Herein, we show that in human dermal
fibroblasts Fli1 works as a transcriptional repressor of the ERa
gene via binding to the proximal region of the ERa promoter.
In response to TGF-b, Fli1 dissociates from the ERa promoter,
suggesting that analogous to the collagen gene, ERa gene
expression might be regulated through the TGF-b/PKC-d/Fli1
pathway (Asano and Trojanowska, 2009). Relevant to our
findings, upregulation of PKC-d was shown to contribute to
the antiestrogen resistance in mammary tumor cells, and
PKC-d was shown to be involved in activation and nuclear
translocation of ERa in those cells (De Servi et al., 2005;
Nabha et al., 2005). Additionally, our study demonstrates that
reduced Fli1 expression correlates with elevated expression
of ERa in mouse dermal fibroblasts in vitro and in vivo.
Interestingly, the effects of Fli1 downregulation on the ERa
expression were more pronounced in vivo than in cultured
fibroblasts, suggesting that additional indirect effects of Fli1
on ERa expression levels may contribute to these effects,
as well.
There is a complex cross-talk between the estrogen/ERa
and TGF-b pathways. In many cell types, estrogen/ERa
potently inhibits Smad2/3, as well as Smad1 signaling
through the molecular interactions between Smads and the
ERa protein (Matsuda et al., 2001; Yamamoto et al., 2002; Ito
et al., 2010), whereas a positive effect on Smad signaling was
observed in prolactin-producing cells (Giacomini et al.,
2009). Less is known about the reciprocal effects of TGF-b
on estrogen signaling, but an enhancement of ER-mediated
transcription by TGF-b was described in mesangial cells
(Matsuda et al., 2001). In this study we observed upregulation
of ERa in response to TGF-b, suggesting that signaling
through this receptor might be involved in the downstream
effects of TGF-b, including ECM production in dermal
fibroblasts. However, in spite of a large number of studies
documenting stimulatory effects of topical estrogen on
collagen accumulation in the skin (Rittie et al., 2008), the
mechanistic aspects of collagen gene regulation by estrogen
remain poorly understood. Estrogen was also shown to
induce collagen and other matrix proteins in cultured dermal
fibroblasts (Surazynski et al., 2003; Soldano et al., 2010).
Interestingly, the stimulatory effects of estrogen on ECM
synthesis were more pronounced in fibroblasts obtained from
the skin of patients with scleroderma (Soldano et al., 2010).
This may be a result of an augmented PKC-d/Fli1 (Jimenez
et al., 2001; Asano and Trojanowska, 2009) signaling present
in scleroderma fibroblasts. Although further studies are
needed to confirm this observation and to further explore
enhanced sensitivity of scleroderma fibroblasts to estrogen
stimulation, these observations suggest that estrogen may
enhance the fibrotic process in scleroderma possibly as a part
of an activated TGF-b/PKC-d/Fli1 axis.
MATERIALS AND METHODS
Reagents
Recombinant human TGF-b1 was obtained from Peprotech (Locky
Hill, NJ). Tamoxifen and E2-17b-estradiol were purchased from
EMD4Biosciences (Gibbstown, NJ). The polyclonal rabbit anti-Fli1
antibody was purchased from Santa Cruz Biotechnology (Santa Cruz,
CA); goat anti-type I collagen was from Southern Biotech
(Birmingham, AL).
Cell culture
Human dermal fibroblast culture was established from skin biopsies
from dorsal forearm of healthy donors, upon informed consent and
in compliance with the institutional review board for human studies.
The study was conducted according to the Declaration of Helsinki
Principles. All healthy donors were adult young women (range
19–34 years old) to exclude differences based on sex. Human and
mouse skin tissue was dissociated enzymatically by 0.25%
collagenase (Sigma, St Louis, MO) and 0.05% DNase (Sigma) in
DMEM (Gibco BRL, Grand Island, NY) with 20% fetal bovine serum
(HyClone, Logan, UT). Digested tissue was placed in a six-well plate
in 2ml of DMEM with 10% fetal bovine serum and grown for 3–5
days. The resulting confluent culture was subsequently passaged in
DMEM with 10% fetal bovine serum.
Western blot analysis
Cells were lysed in Lysis buffer (50mM Tris-HCl (pH 8.0), 150mM
NaCl, 3mM MgCl2, 1mM CaCl2, 1% Triton X-100, 1mM phenyl-
methylsulfonyl fluoride (EMD, Gibbstown, NJ), and Protease
inhibitor cocktail set III, EDTA free (EMD)). Protein concentration
was determined by BCA Protein Assay Kit (Thermo Scientific,
Waltham, MA). Equal amounts (50 mg) of total protein samples from
dermal fibroblasts were separated via 10% SDS-PAGE and trans-
ferred to nitrocellulose membranes. Membranes were incubated
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Figure 5. Fli1þ /– fibroblasts show enhanced fibrotic response to tamoxifen
and 17b-estradiol stimulation. Dermal fibroblasts from (a) male and (b)
female Fli1þ /þ and Fli1þ /– mice were stimulated for 24 hours with 17b-
estradiol (1010 M) (E2) or tamoxifen (107 M) (TAM). Collagen a1(I) mRNA
levels were determined by quantitative reverse transcription-PCR (qRT-PCR).
Means±SD of three independent experiments is shown, with values
normalized to control (arbitrarily set at 100). Representative western blot of
collagen protein levels in the conditioned media is shown in the bottom
panels. WT, wild type.
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with Tris-buffered saline containing 3% non-fat dry milk (Bio-Rad,
Hercules, CA) for 1 hour at room temperature, followed by
incubation with rabbit anti-ERa antibody (G-20, Santa Cruz
Biotechnology) for detection of human ERa and MC-20 (Santa Cruz)
for detection of mouse ERa in a dilution of 1:500 or rabbit anti-Fli1
antibody in a dilution of 1:2,000 overnight at 4 1C. To control for
protein loading, blots were probed for b-actin expression using
monoclonal anti-b-actin antibody (Sigma). After incubation with
horseradish peroxidase-conjugated secondary antibody (GE Health-
care, Piscataway, NJ) in a dilution of 1:5,000, the signals were
visualized using enhanced chemiluminescence reagents (Thermo
Scientific).
Quantitative RT-PCR analysis
Total RNA was isolated using Tri reagent (MRC, Cincinnati, OH).
Then, 2mg of total RNA was reverse transcribed with random
hexamers using a Transcriptor First Strand complementary DNA
Synthesis kit (Roche Applied Science, Indianapolis, IN) according to
the manufacturer’s protocol. Real-time PCR assays were performed
using the StepOnePlus Real-Time PCR system (Applied Biosystems,
Foster City, CA). The amplification mixture (10 ml) contained 1 ml of
complementary DNA, 0.5mM of each primer, and 5ml of SYBR Green
PCR Master Mix. The primers are listed in the Supplementary Table
S1 online. To quantify mRNA expression of human ERa, real-time
TaqMan PCR was performed. Validated primer/probe set directed
toward the exon 3–4 boundaries (Hs00174860_m1; Applied
Biosystems) was used to amplify the target gene. Complementary
DNA (2ml) was added to 10 ml of TaqMan Gene Expression Master
Mix in the amplification mixture (20 ml). All samples were analyzed
in parallel for gene expressions of either human glyceraldehyde-3-
phosphate dehydrogenase or mouse b2-microglobin as an internal
control by SYBR Green method. The primers are listed in the
Supplementary Table S1 online. Cycling condition consisted of an
initial incubation at 50 1C for 2minutes and 95 1C for 10minutes,
followed by 40 cycles of 95 1C for 15 seconds and 58 1C for 1minute.
The relative change in the levels of genes of interest was determined
by the 2DDCT method.
Suppression of Fli1 by siRNA
Cells were transfected with either siRNA specific to human Fli1 (ON-
TARGETplus SMART pool; Thermo scientific) or negative control
siRNA (Qiagen, Valencia, CA) at the concentration of 10 nM using
HiPerfect reagent (Qiagen) according to the manufacturer’s protocol.
After 72 hours, total protein and RNA were extracted. To remove the
effect of serum, cells were serum-starved for the last 24 hours.
RT-PCR analysis
For analysis of ERa transcripts, PCR was performed with Taq DNA
polymerase (New England Biolabs, Ipswich, MA) using the primers
specific to human ERa (Figure 1a) or exon-specific primers (Figure
3b). Reaction without reverse transcription served as a control for
genomic DNA contamination. The primers specific to human ERa
are listed in the Supplementary Table S2A online. As the primer set is
directed toward exon 1–2 boundaries and the splicing variants of
human ERa (46 and 36 kDa isoforms) lack exon 1, mRNAs of the
splicing variants should not be detected in this system. The forward
primers for the ERa mRNAs produced by transcription from
promoters A, B, C, D, E2, and F are listed in the Supplementary
Table S2B online. The reverse primer (Supplementary Table S2B
online) was from exon 1. Cycling conditions were as follows: an
initial 5minute denaturation at 95 1C followed by 45 cycles
consisting of 30 seconds at 95 1C, 30 seconds at 57 1C, and 1minute
at 72 1C. A final extension for 10minutes at 72 1C concluded the
reactions.
ChIP assay
ChIP assay was carried out as described previously (Nakerakanti
et al., 2006). Briefly, cells were treated with 1% formaldehyde
(Sigma) for 10minutes. The crosslinked chromatin was then
collected and sheared by sonication to yield an average size of
300–500 bp. The DNA fragments were immunoprecipitated over-
night with or without polyclonal anti-Fli1 antibody at 4 1C. After
reversal of crosslinking, the immunoprecipitated chromatin was
amplified by regular PCR. The primers are listed in the Supplemen-
tary Table S3 online. The amplified DNA products were resolved by
agarose gel electrophoresis.
DNA affinity precipitation assay
The assay was carried out as described previously (Pannu et al.,
2008). Briefly, cell extracts were prepared in RIPA buffer from
confluent dishes of Hek293T cells transduced with Fli1 adenovirus at
the multiplicity of infection of 5 for 24 hours. The extracts were
precleared with streptavidin-coated agarose beads (Invitrogen,
Carlsbad, CA), and the supernatants were incubated with 500 pmol
of 50 biotinylated double-stranded oligonucleotide, either WT or
mutated (at EBS) (MUT) ERa promoter. After overnight incubation at
4 1C with constant rotation, streptavidin-coated agarose beads were
added to each tube, and the samples were rotated for an additional
2 hours at 4 1C. Beads were recovered by centrifugation and washed
three times with Tris–EDTA followed by two washes with RIPA buffer
and two washes with 1 phosphate-buffered saline. The beads were
suspended in 2 sample loading buffer at 95 1C for 5minutes. The
supernatants were separated by 10% SDS-PAGE and transferred onto
nitrocellulose membrane. Western blotting was performed with
antibody against Fli1 (Invitrogen), and the bands were visualized
using enhanced chemiluminescence reagent (Pierce, Rockford, IL).
The sequences of the forward and reverse oligonucleotides are
shown in the Supplementary Table S4 online.
Transient transfections and luciferase reporter assay
ERa promoter-luciferase plasmid construct was described previously
(deConinck et al., 1995) and was a gift from Dr Ronald J Weigel.
Transient transfection of the ERa promoter plasmid (2 mg) and pSG5
control vector of Fli1 pSGF vector into foreskin fibroblasts was
carried out using Amaxa (Walkersville, MD) electroporation device
according to the manufacturer’s instructions. After overnight
incubation at 37 1C, some cells were further stimulated with TGF-b
for 24 hours. The cells were harvested and Luciferase activity of the
promoter was assayed using Promega Luciferase assay kit as
described previously (Nakerakanti et al., 2006).
Immunohistochemistry
Immunohistochemistry was performed on formalin-fixed, paraffin-
embedded skin tissue sections using a Vectastain ABC kit (Vector
Laboratories, Burlingame, CA) according to the manufacturer’s
instructions. Briefly, sections (5-mm thick) were mounted on APES
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(aminopropyltriethoxy silane solution)-coated slides, deparafinized
with Histo-Clear (National Diagnostics, Atlanta, GA), and rehydrated
through a graded series of ethanol. Endogenous peroxidase was
blocked by incubation in 3% hydrogen peroxide for 30minutes,
followed by incubation with normal blocking serum for 1 hour. The
sections were then incubated overnight at 4 1C with antibody against
ERa (MC-20), diluted 1:100 in blocking buffer, followed by
incubation for 30minutes with biotinylated secondary antibody
solution. The immunoreactivity was visualized with diaminobenzi-
dine (Vector Laboratories), and the sections were counterstained
with methylgreen (Vector Laboratories). Images were collected using
a microscope (BH-2; Olympus, Center Valley, PA).
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